These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20592407)

  • 21. Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support.
    Radtke ML; Kolesar JM
    J Oncol Pharm Pract; 2005 Sep; 11(3):121-5. PubMed ID: 16390600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acanthosis nigricans in a patient treated with palifermin.
    Lee M; Grassi M
    Cutis; 2010 Sep; 86(3):136-7. PubMed ID: 21049730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Palifermin in prevention of head and neck cancer radiation-induced mucositis: not yet a definitive word on safety and efficacy profile.
    Bossi P; Locati LD; Licitra L
    J Clin Oncol; 2012 Feb; 30(5):564-5; 565-567. PubMed ID: 22215750
    [No Abstract]   [Full Text] [Related]  

  • 24. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial.
    Henke M; Alfonsi M; Foa P; Giralt J; Bardet E; Cerezo L; Salzwimmer M; Lizambri R; Emmerson L; Chen MG; Berger D
    J Clin Oncol; 2011 Jul; 29(20):2815-20. PubMed ID: 21670447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Palifermin dose should be adjusted to different therapy regimens.
    Verhagen MP; Wondergem MJ; Visser O
    Bone Marrow Transplant; 2009 Apr; 43(8):665. PubMed ID: 19029966
    [No Abstract]   [Full Text] [Related]  

  • 26. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.
    Rosen LS; Abdi E; Davis ID; Gutheil J; Schnell FM; Zalcberg J; Cesano A; Gayko U; Chen MG; Clarke S
    J Clin Oncol; 2006 Nov; 24(33):5194-200. PubMed ID: 17075109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of palifermin on incidence of oral mucositis and healthcare utilization in children undergoing autologous hematopoietic stem cell transplantation for malignant diseases.
    Vitale KM; Violago L; Cofnas P; Bishop J; Jin Z; Bhatia M; Kung AL; George D; Garvin J; Satwani P
    Pediatr Transplant; 2014 Mar; 18(2):211-6. PubMed ID: 24823628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New drugs; palifermin].
    Cohen AF; Dubois EA; van Bronswijk H
    Ned Tijdschr Geneeskd; 2006 Dec; 150(50):2753-4. PubMed ID: 17225787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.
    Nasilowska-Adamska B; Rzepecki P; Manko J; Czyz A; Markiewicz M; Federowicz I; Tomaszewska A; Piatkowska-Jakubas B; Wrzesien-Kus A; Bieniaszewska M; Duda D; Szydlo R; Halaburda K; Szczepinski A; Lange A; Hellman A; Robak T; Skotnicki A; Jedrzejczak WW; Walewski J; Holowiecki J; Komarnicki M; Dmoszynska A; Warzocha K; Marianska B
    Bone Marrow Transplant; 2007 Nov; 40(10):983-8. PubMed ID: 17846600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effectiveness of palifermin in the prevention of oral mucositis in patients with haematological cancers].
    Ayago Flores D; Ferriols Lisart R
    Farm Hosp; 2010; 34(4):163-9. PubMed ID: 20580585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction of radiochemotherapy-induced early oral mucositis by recombinant human keratinocyte growth factor (palifermin): experimental studies in mice.
    Dörr W; Bässler S; Reichel S; Spekl K
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):881-7. PubMed ID: 15936573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term Safety Outcomes in Patients with Hematological Malignancies Undergoing Autologous Hematopoietic Stem Cell Transplantation Treated with Palifermin to Prevent Oral Mucositis.
    Stiff PJ; Leinonen M; Kullenberg T; Rudebeck M; de Chateau M; Spielberger R
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):164-9. PubMed ID: 26303102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Establishment of an animal model of oral mucositis induced by conditioning regimen of haematopoietic stem cell transplantation].
    Chen XB; Wang X; Tong XZ
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2007 Nov; 42(11):672-6. PubMed ID: 18307925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Palifermin, administered for three doses only, reduces mucositis in patients undergoing HSCT and receiving chemoradiotherapy conditioning.
    Coutsouvelis J; Dooley M; Kirkpatrick CM; Avery S; Hopkins R; Spencer A
    Bone Marrow Transplant; 2022 Aug; 57(8):1329-1331. PubMed ID: 35589999
    [No Abstract]   [Full Text] [Related]  

  • 35. Palifermin-induced flexural hyperpigmentation: a clinical and histological study of five cases.
    Sibelt LA; Aboosy N; van der Velden WJ; Blijlevens NM; Blokx WA; Seyger MM
    Br J Dermatol; 2008 Nov; 159(5):1200-3. PubMed ID: 18795935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Palifermin in a hematopoietic stem cell transplant patient with osteonecrosis of the jaw.
    Yageman LA; Cronin SM; Peres E; Abidi MH; Ibrahim RB
    J Oncol Pharm Pract; 2006 Jun; 12(2):119-21. PubMed ID: 16984751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Palifermin in the preventive treatment of oral mucositis in autograft patients: data on efficacy and tolerance following marketing approval].
    Onteniente S; Coullet V; Chemelle M; Lafont I; Pernot C; Guignard MH
    Therapie; 2008; 63(1):37-42. PubMed ID: 18387274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mucosal damage: a major risk factor for severe complications after cytotoxic therapy.
    Peterson DE; Cariello A
    Semin Oncol; 2004 Jun; 31(3 Suppl 8):35-44. PubMed ID: 15181607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden.
    Blijlevens N; de Château M; Krivan G; Rabitsch W; Szomor A; Pytlik R; Lissmats A; Johnsen HE; de Witte T; Einsele H; Ruutu T; Niederwieser D;
    Bone Marrow Transplant; 2013 Jul; 48(7):966-71. PubMed ID: 23241739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation.
    Schmidt V; Niederwieser D; Schenk T; Behre G; Klink A; Pfrepper C; Hinke A; Beelen DW; Junghanss C; Uharek L; Krüger WH; Hochhaus A; Sayer HG;
    Bone Marrow Transplant; 2018 Sep; 53(9):1188-1192. PubMed ID: 29545592
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.